Related Experiment Video

Updated: May 23, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis

Jian-Hua Zhu1, Ye Yuan, Dong Li

  • 1Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Cancer Science
|April 13, 2012
PubMed

Insights

Toll-like receptor 4 (TLR4) ligands hinder anti-metastasis therapy targeting αvβ3. Inhibiting nuclear factor-κB (NF-κB) with TLR4 ligands restores therapy efficacy, suggesting a combined treatment approach for cancer metastasis.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Targeting αvβ3 integrins is a key strategy to inhibit tumor metastasis.
  • The influence of metastasis-promoting factors on αvβ3-targeted therapies remains largely unknown.

Purpose of the Study:

  • To investigate the impact of Toll-like receptor 4 (TLR4) ligands on the efficacy of αvβ3-targeted therapy.
  • To explore the underlying mechanisms and potential combination strategies for enhancing anti-metastasis treatment.

Main Methods:

  • Utilized a recombinant fibronectin polypeptide (CH50) targeting αvβ3.
  • Assessed the effects of TLR4 ligands on tumor cell adhesion, invasion, survival, and metastasis in vivo.
  • Investigated the role of nuclear factor-κB (NF-κB) signaling pathway.
  • Evaluated the combination therapy of an NF-κB inhibitor and CH50.

Main Results:

  • TLR4 ligands antagonized CH50's anti-metastasis effects by upregulating αvβ3 expression and activity.
  • TLR4 ligands promoted tumor cell survival in circulation and post-extravasation, increasing metastatic nodules.
  • NF-κB signaling mediated the suppressive effects of TLR4 ligands.
  • Combined NF-κB inhibition and CH50 significantly reduced metastasis and improved survival in mice.

Conclusions:

  • TLR4 signaling negatively impacts αvβ3-targeted anti-metastasis therapy.
  • Inhibiting NF-κB abrogates TLR4-mediated suppression and enhances therapeutic efficacy.
  • Combination therapy with NF-κB inhibitors and αvβ3 antagonists presents a promising strategy for preventing cancer metastasis.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...